Sign up to save your podcasts
Or
Share Deep dive into targeted therapies: understanding IDH1-mutant AML treatments | S6E3
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Deep dive into targeted therapies: understanding IDH1-mutant AML treatments | S6E3
The AML expert series: Innovations in molecular testing, emerging therapies & targeted treatments
In this episode Prof. Amer Zeidan, MBBS, MHS, and Prof. Courtney D. DiNardo,MD, MSCE, discuss mechanisms of action, efficacy, and safety profiles of novel targeted therapies for IDH1-mutant relapsed/refractory acute myeloid leukemia (R/R AML).
To access the video-based podcast episode, and learn more about the full series on molecular testing and targeted treatments for improved patient outcomes in R/R AML, visit https://springermedicine.com/aml-expert-series-overview/50892434
Intended for healthcare professionals only.
Supported by an independent educational grant from Rigel.
© 2025 Springer Healthcare LLC. Springer Health+ IME is part of Springer Nature. All rights reserved.
View all episodes
By Springer Health+ IMEThe AML expert series: Innovations in molecular testing, emerging therapies & targeted treatments
In this episode Prof. Amer Zeidan, MBBS, MHS, and Prof. Courtney D. DiNardo,MD, MSCE, discuss mechanisms of action, efficacy, and safety profiles of novel targeted therapies for IDH1-mutant relapsed/refractory acute myeloid leukemia (R/R AML).
To access the video-based podcast episode, and learn more about the full series on molecular testing and targeted treatments for improved patient outcomes in R/R AML, visit https://springermedicine.com/aml-expert-series-overview/50892434
Intended for healthcare professionals only.
Supported by an independent educational grant from Rigel.
© 2025 Springer Healthcare LLC. Springer Health+ IME is part of Springer Nature. All rights reserved.